Weight Considerations in Psychotropic Drug Prescribing and Switching

References

• . Russell L. Mental Health Care Services in Primary Care — Tackling the Issues in the Context of Health Care Reform. http://www.american-progress.org/wp-content/uploads/issues/2010/10/pdf/mentalhealth.pdf Center for American Progress. Acessed February 26, 2013
   Google Scholar
• . Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry. 2007;64(2):242–249
   PubMed Web of Science ®Google Scholar
• . Luppino FS, de Wit LM, Bouvy PF, . Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–229
   PubMed Web of Science ®Google Scholar
• . Brumpton B, Langhammer A, Romundstad P, Chen Y, Mai XM. The associations of anxiety and depression symptoms with weight change and incident obesity: The HUNT Study. Int J Obes (Lond). 2012. doi:10.1038/ijo.2012.204. [Epub ahead of print]
   Google Scholar
• . Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes. 2009;3(1):5–15
   PubMedGoogle Scholar
• . Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med. 2012;124(4):154–167
   PubMed Web of Science ®Google Scholar
• . Vieweg WV, Levy JR, Fredrickson SK, . Psychotropic drug considerations in depressed patients with metabolic disturbances. Am J Med. 2008;121(8):647–655
   PubMedGoogle Scholar
• . Lieberman JA, Stroup TS, McEvoy JP, ; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223
   PubMed Web of Science ®Google Scholar
• . Sikich L, Frazier JA, McClellan J, . Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165(11):1420–1431
   PubMed Web of Science ®Google Scholar
• . Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 2007;93(1–3):90–98
   PubMed Web of Science ®Google Scholar
• . Kahn RS, Fleischhacker WW, Boter H, ; EUFESTstudy group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097
   PubMed Web of Science ®Google Scholar
• . McEvoy JP, Lieberman JA, Perkins DO, . Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–1060
   PubMed Web of Science ®Google Scholar
• . Parsons B, Allison DB, Loebel A, . Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1–3):103–110
   PubMed Web of Science ®Google Scholar
• . Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19( Suppl 1):1–93
   PubMed Web of Science ®Google Scholar
• . Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72( Suppl 1):19–23
   PubMedGoogle Scholar
• . Citrome L, Cucchiaro J, Sarma K, . Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165–176
   PubMed Web of Science ®Google Scholar
• . De Hert M, Yu W, Detraux J, Sweers K, van WR, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733–759
   PubMed Web of Science ®Google Scholar
• . Potkin SG. Asenapine: a clinical overview. J Clin Psychiatry. 2011;72( Suppl 1):14–18
   PubMedGoogle Scholar
• . Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry. 2012;45(5)196–203
   PubMed Web of Science ®Google Scholar
• . Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull. 1995;21(3):463–472
   PubMedGoogle Scholar
• . Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, . Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs. 2008;22(7):547–562
   PubMed Web of Science ®Google Scholar
• . Moreno C, Merchan-Naranjo J, Alvarez M, . Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord. 2010;12(2):172–184
   PubMed Web of Science ®Google Scholar
• . Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? Psychiatry Res. 2009;170(2–3):172–176
   PubMedGoogle Scholar
• . Simon V, van WR, De HM. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041–1050
   PubMed Web of Science ®Google Scholar
• . Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs. 2009;23(10):837–855
   PubMedGoogle Scholar
• . Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther. 2005;27(12):1930–1941
   PubMed Web of Science ®Google Scholar
• . Montes JM, Rodriguez JL, Balbo E, . Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):383–388
   PubMedGoogle Scholar
• . De Hert M, Hanssens L, van Winkel R, . A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull. 2007;33(3):823–830
   PubMedGoogle Scholar
• . Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA . The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93
   PubMed Web of Science ®Google Scholar
• . Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F . A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–163
   PubMed Web of Science ®Google Scholar
• . Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41
   PubMed Web of Science ®Google Scholar
• . McCue RE, Unuigbe FE, Charles RA, Orendain GC, Waheed R. Treatment of morbidly obese psychotic patients with molindone: three case reports. J Clin Psychiatry. 2009;70(11):1606–1607
   PubMedGoogle Scholar
• . U. S. Food and Drug Administration. Drugs@FDA. FDA approved drug products, http://www.accessdata.fdagov/scripts/cder/drugsatfda/index.cfm Acessed February 26, 2013
   Google Scholar
• . Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73(4):486–496
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601
   PubMed Web of Science ®Google Scholar
• . Hasnain M, Vieweg WV. Do we truly appreciate how difficult it is for patients with schizophrenia to adapt a healthy lifestyle? Acta Psychiatr Scand. 2011;123(6):409–410
   PubMedGoogle Scholar
• . Lambert TJ, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust. 2009;190( 4 Suppl):S39–S42
   PubMed Web of Science ®Google Scholar
• . Vieweg WV, Hasnain M, Pandurangi AK. Coordinated medical and psychiatric care in schizophrenia. Am J Med. 2012;125(3):219–220
   PubMedGoogle Scholar
• . Mark TL, Levit KR, Buck JA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 2009;60(9):1167
   PubMedGoogle Scholar
• . Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259–1272
   PubMed Web of Science ®Google Scholar
• . National Institutes of Health/Agency for Healthcare Quality and Research.Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux LJ, Van NM . Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. http://www.ncbi.nlm.nih.gov/books/NBK83442/pdf/TOC.pdf Acessed February 26, 2013
   Google Scholar
• . Wise TN, Perahia DG, Pangallo BA, Losin WG, Wiltse CG. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 2006;8(5):269–278
   PubMedGoogle Scholar
• . Tourian KA, Leurent C, Graepel J, Ninan PT. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12(1):PCC.08m00746
   PubMedGoogle Scholar
• . Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant — what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2012;66(4):356–368
   PubMed Web of Science ®Google Scholar
• . Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(8):1128–1137
   PubMed Web of Science ®Google Scholar
• . Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the side-effect profile of buspirone. Am J Med. 1986;80(3B):17–21
   PubMed Web of Science ®Google Scholar
• . Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J. 1990;83(2):194–198
   PubMedGoogle Scholar
• . Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor — and imipramine-controlled trials. J Clin Psychiatry. 2001;62(4):256–260
   PubMed Web of Science ®Google Scholar
• . Papakostas Gl, Hornberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol. 2008;22(8):843–848
   PubMedGoogle Scholar
• . Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008;68(5):653–689
   PubMed Web of Science ®Google Scholar
• . Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149(10):725–733
   PubMed Web of Science ®Google Scholar
• . Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75(1):57–66
   PubMed Web of Science ®Google Scholar
• . Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43–64
   PubMed Web of Science ®Google Scholar
• . Hoffman EJ, Mathew SJ. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008;75(3):248–262
   PubMedGoogle Scholar
• . Torrent C, Amann B, Sanchez-Moreno J, Colom F, . Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118(1):4–18
   PubMed Web of Science ®Google Scholar
• . Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol. 1988;8(5):323–330
   PubMedGoogle Scholar
• . El-Khatib F, Rauchenzauner M, Lechleitner M, . Valproate, weight gain and carbohydrate craving: a gender study. Seizure. 2007;16(3):226–232
   PubMedGoogle Scholar
• . Geller B, Luby JL, Joshi P, Wagner KD, . A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012;69(5):515–528
   PubMed Web of Science ®Google Scholar
• . Brown E, Dunner DL, McElroy SL, . Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009;12(6):773–782
   PubMed Web of Science ®Google Scholar
• . Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U. S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58(1):85–91
   PubMed Web of Science ®Google Scholar
• . Bond DJ, Kunz M, Torres IJ, Lam RW, Yatham LN. The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Bipolar Disord. 2010;12(6):616–626
   PubMedGoogle Scholar
• . Langosch JM, Drieling T, Biedermann NC, . Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. J Clin Psychopharmacol. 2008;28(5):555–560
   PubMed Web of Science ®Google Scholar
• . Cardinali DP, Bernasconi PA, Reynoso R, Toso CF, Scacchi P. Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats. Int J Mol Sci. 2013;14(2):2502–2514
   PubMedGoogle Scholar
• . Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology. 2007;32(2):284–288
   PubMed Web of Science ®Google Scholar
• . Oxenkrug GF, Summergrad P. Ramelteon attenuates age-associated hypertension and weight gain in spontaneously hypertensive rats. Ann NY Acad Sci. 2010;1199:114–120
   PubMed Web of Science ®Google Scholar
• . Borba CP, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacol. 2011;31(5):653–658
   PubMedGoogle Scholar
• . Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring). 2010;18(12):2398–2400
   PubMedGoogle Scholar
• . Roth T, Rogowski R, Hull S, . Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30(11):1555–1561
   PubMed Web of Science ®Google Scholar
• . Morin CM, LeBlanc M, Daley M, Gregoire JP, Merette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7(2):123–130
   PubMed Web of Science ®Google Scholar
• . McDonagh MS, Peterson K, Thakurta S, Low A. Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder. Final Update 4 Report [Internet]. Portland (OR): Oregon Health & Science University. 2011. Drug Class Reviews.
   Google Scholar
• . Biederman J, Melmed RD, Patel A, . Arandomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73–e84
   PubMed Web of Science ®Google Scholar
• . Adler LA, Orman C, Starr HL, . Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011;31(1):108–114
   PubMed Web of Science ®Google Scholar
• . Weber J, Siddiqui MA. Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults. CNS Drugs. 2009;23(5):419–425
   PubMedGoogle Scholar
• . Adler LA, Spencer TJ, Williams DW, Moore RJ, Michelson D. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008;12(3):248–253
   PubMed Web of Science ®Google Scholar
• . Kooij SJ, Bejerot S, Blackwell A, . European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67
   PubMed Web of Science ®Google Scholar
• . , Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and ManagementWolraich M, Brown L, Brown RT, . ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–1022
   PubMed Web of Science ®Google Scholar
• . Pagoto SL, Curtin C, Lemon SC, . Association between adult attention deficit/hyperactivity disorder and obesity in the US population. Obesity (Silver Spring). 2009;17(3):539–544
   PubMed Web of Science ®Google Scholar
• . Aagaard L, Hansen EH. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat. 2011;7:729–744
   PubMed Web of Science ®Google Scholar
• . Jafarinia M, Mohammadi MR, Modabbernia A, . Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharmacol. 2012;27(4):411–418
   PubMedGoogle Scholar
• . Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci. 2011;65(7):611–617
   PubMed Web of Science ®Google Scholar
• . Lee MW, Fujioka K. Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother. 2009;10(11):1841–1845
   PubMed Web of Science ®Google Scholar
• . Greenway FL, Fujioka K, Plodkowski RA, . Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605
   PubMed Web of Science ®Google Scholar
• . Hudson SM, Whiteside TE, Lorenz RA, Wargo KA. Prazosin for the treatment of nightmares related to posttraumatic stress disorder: a review of the literature. Prim Care Companion CNS Disord. 2012;14(2). pii: PCC.11r01222
   Google Scholar
• . Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ. 2012;345:e4439
   PubMed Web of Science ®Google Scholar
• . Fossati R, Apolone G, Negri E, . A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med. 2007;167(16):1791–1797
   PubMedGoogle Scholar
• . Lam S, Patel PN. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol Rev. 2007;15(3):154–161
   PubMedGoogle Scholar
• . Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005;331(7512):321–327
   PubMedGoogle Scholar
• . Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine forthe treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–225
   PubMed Web of Science ®Google Scholar
• . Kavirajan H. Memantine: a comprehensive review of safety and efficacy. Expert Opin Drug Saf. 2009;8(1):89–109
   PubMed Web of Science ®Google Scholar
• . Kessler RC, Gruber M, Hettema JM, Hwang I, Sampson N, Yonkers KA. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med. 2008;38(3):365–374
   PubMed Web of Science ®Google Scholar
• . McGough JJ, Smalley SL, McCracken JT, . Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry. 2005;162(9):1621–1627
   PubMed Web of Science ®Google Scholar
• . Kim B, Kim SJ, Son JI, Joo YH. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord. 2008;105(1–3):45–52
   PubMed Web of Science ®Google Scholar
• . Seo HJ, Jung YE, Woo YS, Jun TY, Chae JH, Bahk WM. Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Hum Psychopharmacol. 2009;24(2):135–143
   PubMedGoogle Scholar
• . Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011;5(1):17–25
   PubMedGoogle Scholar